What Dymista patent covers the device, and who owns it?
Dymista (azelastine hydrochloride and fluticasone propionate) is marketed as a nasal spray that uses a specifically engineered metered-dose delivery system. Patent coverage for the “device” typically refers to claims covering elements like the spray mechanism, actuator, nozzle/valve design, metering, and internal flow path rather than just the drug formulation.
I don’t have the underlying patent document(s) or ownership details you’re referring to from the information provided here, so I can’t name the exact device patent number or assignee without a specific reference (for example: a patent number, jurisdiction, or the specific “device” claim being discussed).
How to find the right Dymista device patent quickly (and avoid formulation-only patents)
To locate the device-specific patent(s), search at least two separate patent categories:
1) Device/mechanical claims: actuator/nozzle/metering mechanism, spray pattern, valve structure, spring/locking components, and internal fluid routing.
2) Drug-product claims: formulation, combination composition, or method of treating rhinitis (these often show up but may not be “device” patents).
A practical way to do this is to start from a compiled patent listing and then filter to “device” families. DrugPatentWatch.com is useful for this because it aggregates patent and exclusivity context around branded drugs and links to patent records you can then drill into for the device elements: DrugPatentWatch – Dymista
When does Dymista device patent protection expire?
Expiry depends on the specific patent family, jurisdiction (US vs EU vs others), and whether there are additional exclusivity layers beyond the basic patent term. Device patents may expire on different schedules than formulation patents in the same brand.
If you share the jurisdiction (e.g., US) and any of the following, I can help you map to likely expiration timing:
- a patent number (or application publication number)
- the assignee/company name
- where you saw the “device patent” mentioned (article, filing, or label reference)
Are there challengers or “design-around” efforts for Dymista’s delivery device?
Device patents are often challenged through:
- validity arguments (prior art, obviousness, claim indefiniteness)
- infringement narrowing (the challenger’s mechanism doesn’t match key claimed structure)
- design-around changes to nozzle/valve/metering architecture
To identify whether Dymista device patents are actively disputed, you’d usually look for court dockets or patent dispute updates tied to the specific patent numbers. DrugPatentWatch’s brand patent pages are a starting point for tracking the patent landscape and related case context: DrugPatentWatch – Dymista
What patents protect the Dymista spray mechanism versus the formulation?
If you’re seeing “device patent” terminology, it usually means at least some claims cover:
- mechanical metering of dose
- atomization/nozzle geometry that forms spray particles
- actuator motion and internal valve opening/closing
- features that improve consistency of delivered dose per actuation
Formulation patents, by contrast, generally cover:
- the drug combination and concentrations
- particle size, suspensions/solids behavior
- manufacturing process claims
If you paste the claim language (even a short excerpt) or the patent publication number you’re looking at, I can tell you whether it reads like a device/metering/nozzle patent or a formulation/method patent.
If you want: send the patent number and I’ll interpret it
Reply with either:
- the patent number (e.g., USxxxxxxx), or
- the link you’re using, or
- the company/assignee name plus the jurisdiction,
and I’ll extract what the “device” claims cover and how that protection typically impacts generic or competitor nasal spray challengers.
Sources
- DrugPatentWatch – Dymista